Press Releases News Category Company ReleasesCompany StatementsFinancial ReleasesProduct Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006None Search Date Title PDF Version May 23, 2024 AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) Apr 08, 2024 Alexion data at AAN 2024 demonstrate how ULTOMIRIS® and SOLIRIS® can transform outcomes for rare neurological diseases Apr 01, 2024 VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH Mar 25, 2024 ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) Dec 10, 2023 Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis Nov 29, 2023 AstraZeneca advances scientific leadership in hematology at ASH 2023 Sep 20, 2023 Alexion completes purchase and licence agreement for early-stage rare disease gene therapy portfolio from Pfizer Sep 06, 2023 Update on US regulatory review of ULTOMIRIS® in NMOSD Jul 28, 2023 Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies Jun 09, 2023 Danicopan as add-on to ULTOMIRIS® or SOLIRIS® improved hemoglobin levels and maintained disease control in patients with PNH experiencing signs or symptoms of clinically significant extravascular hemolysis Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 631